|
Duration of variable-length baseline period (years), mean (SD)
|
3.4 (1.8)
|
3.5 (1.8)
|
3.5 (1.8)
|
|
Age at index date (years), mean (SD)
|
45.6 (16.5)
|
48.7 (18.0)
|
45.8 (17.1)
|
|
Gender, n (%)
|
|
Female
|
113 (50.2)
|
188 (50.4)
|
466 (49.6)
|
|
Male
|
112 (49.8)
|
185 (49.6)
|
474 (50.4)
|
|
Biologic treatment history, n (%)
|
|
Biologic-naïve
|
43 (19.1)
|
307 (82.3)
|
881 (93.7)
|
|
1 prior biologic
|
92 (40.9)
|
49 (13.1)
|
49 (5.2)
|
|
≥ 2 prior biologics
|
90 (40.0)
|
17 (4.6)
|
10 (1.1)
|
|
Oral corticosteroid use, n (%)a
|
173 (76.9)
|
254 (68.1)
|
693 (73.7)
|
|
Geographic region, n (%)
|
|
Northeast
|
26 (11.6)
|
46 (12.3)
|
102 (10.9)
|
|
Midwest
|
49 (21.8)
|
108 (29.0)
|
263 (28.0)
|
|
South
|
97 (43.1)
|
162 (43.4)
|
427 (45.4)
|
|
West
|
53 (23.6)
|
57 (15.3)
|
148 (15.7)
|
|
12-month baseline Quan-Charlson comorbidity score, mean (SD)
|
0.7 (1.3)
|
0.8 (1.5)
|
0.8 (1.3)
|
|
12-month baseline Quan-Charlson comorbidity score, n (%)
|
|
0
|
152 (67.6)
|
233 (62.5)
|
602 (64.0)
|
|
1
|
34 (15.1)
|
57 (15.3)
|
154 (16.4)
|
|
2
|
23 (10.2)
|
48 (12.9)
|
97 (10.3)
|
|
3
|
8 (3.6)
|
13 (3.5)
|
45 (4.8)
|
|
4
|
3 (1.3)
|
9 (2.4)
|
22 (2.3)
|
|
≥ 5
|
5 (2.2)
|
13 (3.5)
|
20 (2.1)
|
